Mitsui Ventures 三井ベンチャーズ(MVC、MCVP) ベンチャーキャピタル ベンチャー 三井物産 起業

NEWS 2005

[02/07/2005]

Cylene Pharmaceuticals Moves Headquarters and R&D Operations to State-of-the-Art San Diego Facility

Cylene Pharmaceuticals, an oncology drug discovery and development company, today announced that it has relocated its corporate headquarters and R&D operations to 5820 Nancy Ridge Drive Suite 200, in the heart of San Diego's biotechnology center. The facility includes approximately 15,000 square feet of laboratory and office space.

"Cylene Pharmaceuticals' new headquarters will accommodate the company's growth needs in a facility designed specifically to accommodate state-of-the-art drug discovery and development activities," said William Rice, Ph.D., president and CEO of Cylene Pharmaceuticals. "We are at an exciting stage of growth as we continue to advance our therapeutic pipeline of quadruplex targeting agents into the clinic. The most advanced product candidate is CX-3543, our first-in-class compound directed against a unique DNA structure involved in the transcription and replication of a variety of oncogenes."

About Cylene Pharmaceuticals, Inc.

Cylene Pharmaceuticals is a biotech pharmaceutical company dedicated to the discovery, development and commercialization of targeted small-molecule drugs to treat life-threatening cancers. Using its proprietary Ribosomal RNA Biosynthesis Inhibition Technology (RABIT?) to design molecules that combat drug-resistant forms of cancer, Cylene has created multiple product candidates in different stages of development. Cylene's most advanced cancer agent, CX-3543, is a Ribosomal RNA Biogenesis Inhibitor (RBI) in late-stage Phase 1 clinical development. More information can be found at www.cylenepharma.com

http://www.cylenepharma.com/

Cylene's New Contact Information

Cylene Pharmaceuticals
5820 Nancy Ridge Drive, Suite 200
San Diego, CA 92121
Telephone: (858) 875-5100
Fax: (858) 875-5101
E-Mail(General Information): info@cylenepharma.com